Eteplirsen treatment for Duchenne muscular dystrophy
Jay S. Charleston(Nationwide Children's Hospital), Jerry R. Mendell(Nationwide Children's Hospital), Zarife Sahenk(The Ohio State University), J. Dworzak(Nationwide Children's Hospital), Diane E. Frank(Nationwide Children's Hospital), Anthony J. Milici(Nationwide Children's Hospital), Jon Voss(Nationwide Children's Hospital), C. Donoghue(Nationwide Children's Hospital), Sarah Lewis(Nationwide Children's Hospital), Bruce M. Wentworth(Sarepta Therapeutics (United States)), Lei Chen(Shanxi University), Geoffrey D. Young(Nationwide Children's Hospital), Louise R. Rodino‐Klapac(Sarepta Therapeutics (United States)), Frederick J. Schnell(Nationwide Children's Hospital), U. DeAlwis(Nationwide Children's Hospital)
Cited by 231
Related Papers
Evidence‐based path to newborn screening for duchenne muscular dystrophy
|Annals of Neurology|2012|816
Eteplirsen for the treatment of Duchenne muscular dystrophy
|Annals of Neurology|2013|793
Dystrophin Immunity in Duchenne's Muscular Dystrophy
|New England Journal of Medicine|2010|655
Clinical trial in duchenne dystrophy. I. The design of the protocol
|Muscle & Nerve|1981|563
Myoblast Transfer in the Treatment of Duchenne's Muscular Dystrophy
|New England Journal of Medicine|1995|522